{
    "clinical_study": {
        "@rank": "36944", 
        "arm_group": {
            "arm_group_label": "Non-SOS", 
            "arm_group_type": "Other"
        }, 
        "brief_summary": {
            "textblock": "The primary objective of the Post-Randomization Phase Cohort Study is to continue to assess\n      the safety of non-emergency PCI performed at hospitals without cardiac surgery on-site in\n      patients with myocardial ischemia (other than ST-segment elevation myocardial infarction\n      [STEMI])."
        }, 
        "brief_title": "The MASS COMM Post-Randomization Phase Cohort Study", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "The MASS COMM Post-Randomization Phase Cohort Study (\"Cohort Study\" is a prospective,\n      multi-center, single-arm study of non-emergency PCI performed at non-SOS hospitals in\n      patients with myocardial ischemia (other than STEMI). The Cohort Study is designed to allow\n      non-SOS hospitals to continue to perform non-emergency PCI after enrollment to the MASS COMM\n      trial is completed and before the 30-day and 12-month results are available.\n\n      Specifically, all eligible subjects, after enrollment to the MASS COMM randomized controlled\n      trial is completed and before the final results are available and a decision is reached by\n      the MA-DPH, will be consented and enrolled into this Cohort Study. Subjects will be followed\n      through 30 days post procedure."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Candidates for this study must meet ALL of the following criteria:\n\n          -  Subject is at least 18 years old.\n\n          -  Subject requires single- or multi-vessel percutaneous coronary intervention (PCI) of\n             de novo or restenotic target lesion (including in-stent restenotic lesions). N.B.\n             staged procedure will not be considered to meet the endpoint component of repeat\n             revascularization if either of the following pre-catheterization procedure qualifying\n             clinical laboratory values are met:\n\n               -  eGFR is less than 60 ml/min or\n\n               -  creatinine is greater than 1.5 mg/dl\n\n          -  Subject's lesion(s) is (are) amenable to stent treatment with currently available\n             FDA-approved bare metal or drug eluting stents.\n\n          -  Subject is an acceptable candidate for non-emergency, urgent or emergency CABG.\n\n          -  Subject has clinical evidence of ischemic heart disease in terms of a positive\n             functional study, or documented symptoms.\n\n          -  Documented stable angina pectoris [Canadian Cardiovascular Society Classification\n             (CCS) 1, 2, 3, or 4], unstable angina pectoris with documented ischemia (Braunwald\n             Class IB-C, IIB-C, or IIIB-C), non-ST segment elevation myocardial infarction, or\n             documented silent ischemia.\n\n          -  Subject and the treating physician agree that the subject will comply with all\n             follow-up evaluations.\n\n          -  Subject has been informed of the nature and purpose of the study and agrees to its\n             provisions and has provided written informed consent as approved by the Institutional\n             Review Board/Ethics Committee of the respective clinical site.\n\n        Angiographic Inclusion Criteria\n\n          -  The target lesion(s) is (are) de novo or restenotic (including in-stent restenotic)\n             native coronary artery lesion(s) with greater or equal to 50 and less than 100%\n             stenosis (visual estimate), or the target lesion is an acute (less than 1 month)\n             total occlusion as evidenced by clinical symptoms.\n\n          -  If Fractional Flow Reserve (FFR) is measured, target lesion(s) has (have) evidence of\n             a hemodynamically significant stenosis determined by FFR measurement (FFR less than\n             or equal to 0.8).\n\n          -  Target lesions(s) is (are) located in an infarct (if not treated with primary PCI) or\n             non-infarct-related artery with a 70% or greater stenosis (by visual estimate)\n             greater than 72 hours following the STEMI.\n\n        Lesions treated with PCI greater than 72 hours following STEMI would be subject to the\n        same protocol inclusion/exclusion criteria listed above and below with the exception that\n        a target lesion of 70% or greater stenosis may be treated with or without symptoms or\n        abnormal stress test).\n\n        Exclusion Criteria:\n\n        Subjects will be excluded from participation in the Cohort Study (and non-emergency PCI\n        may not be performed in these patients at the non-SOS site) if ANY of the following\n        conditions apply:\n\n          -  The patient is pregnant or breastfeeding.\n\n          -  Evidence of ST segment elevation myocardial infarction within 72 hours of the\n             intended treatment on infarct related or non-infarct related artery.\n\n          -  Cardiogenic shock on presentation or during current hospitalization.\n\n          -  Left ventricular ejection fraction less than 20%.\n\n          -  Known allergies to: aspirin, clopidogrel (Plavix), prasugrel (Effient), and\n             ticlopidine (Ticlid), heparin, bivalirudin, stainless steel, or contrast agent (which\n             cannot be adequately premedicated).\n\n          -  A platelet count less than 75,000 cells/mm3 or greater than 700,000 cells/mm3 or a\n             WBC less than 3,000 cells/mm3.\n\n          -  Acute or chronic renal dysfunction (creatinine less than 2.5 mg/dl or less than\n             150\u00b5mol/L).\n\n          -  Subject is currently participating in an investigational drug or device study that\n             has not completed the primary endpoint or that clinically interferes with the current\n             study endpoints.  (Note: Trials requiring extended follow-up for products that were\n             investigational, but have since become commercially available, are not considered\n             investigational trials).\n\n          -  Prior participation in the MASS-COMM Trial, unless the patient has completed the\n             12-month follow-up for the Trial, and/or prior participation in the Cohort Study,\n             unless the patient has completed the 30-day follow-up for the Cohort Study.\n\n          -  Within 30 days prior to the index Cohort Study procedure, the subject has undergone a\n             previous coronary interventional procedure of any kind.  Note: This exclusion\n             criterion does not apply to post-STEMI patients.\n\n          -  Stroke or transient ischemic attack within the prior 3 months.\n\n          -  Active peptic ulcer or upper GI bleeding within the prior 3 months.\n\n          -  Subject has active sepsis.\n\n          -  Unprotected left main coronary artery disease (stenosis greater than 50%).\n\n          -  Subject has evidence of a hemodynamically insignificant stenosis determined by FFR\n             measurement (FFR greater than 0.8).\n\n          -  In the investigator's opinion, subject has a co-morbid condition(s) that could limit\n             the subject's ability to participate in the study or comply with follow-up\n             requirements or impact the scientific integrity of the study.\n\n        Angiographic Exclusion Criteria\n\n          -  Subject has normal or insignificant coronaries (i.e., coronary lesion(s) less than\n             50% stenosis).\n\n          -  Any target vessel has evidence of:\n\n               1. excessive thrombus (e.g., requires target vessel thrombectomy)\n\n               2. tortuosity (greater than 60 degree angle) that makes it unsuitable for proper\n                  stent delivery and deployment,\n\n               3. heavy calcification.\n\n          -  Any target lesion requires treatment with a device other than PTCA prior to stent\n             placement (e.g. but not limited to, directional coronary atherectomy, excimer laser,\n             rotational atherectomy, etc.).\n\n          -  Any lesion that is located in a saphenous vein graft, however, lesions located within\n             the native vessel but accessed through the graft are eligible.\n\n          -  The target vessel is in a \"last remaining\" epicardial vessel (e.g., >2 non-target\n             epicardial vessels and the bypass grafts to these territories [if present] are\n             totally occluded)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "2789", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02072421", 
            "org_study_id": "DPH00-Cohort"
        }, 
        "intervention": {
            "arm_group_label": "Non-SOS", 
            "intervention_name": "PCI", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 24, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brockton", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02301"
                    }, 
                    "name": "Good Samaritan Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brockton", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02302"
                    }, 
                    "name": "Brockton Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Framingham", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01702"
                    }, 
                    "name": "Metrowest Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lawrence", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01842"
                    }, 
                    "name": "Lawrence General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lowell", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01824"
                    }, 
                    "name": "Saints Memorial Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lowell", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01854"
                    }, 
                    "name": "Lowell General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melrose", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02176"
                    }, 
                    "name": "Melrose-Wakefield Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Methuen", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01844"
                    }, 
                    "name": "Holy Family Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norwood", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02062"
                    }, 
                    "name": "Norwood Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Weymouth", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02190"
                    }, 
                    "name": "South Shore Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective, Multi-center, Non-Randomized, Single-arm, Open-label Study of Percutaneous Coronary Intervention in Community Hospitals Without Cardiac Surgery-On-Site", 
        "overall_official": [
            {
                "affiliation": "Boston University School of Medicine , Boston Medical Center", 
                "last_name": "Alice K Jacobs, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Brigham and Women's Hospital", 
                "last_name": "Laura Mauri, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Harvard Medical School", 
                "last_name": "Sharon-Lise Normand, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: n/a", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "MACE is a composite of all cause mortality, myocardial infarction (Q wave and non-Q wave), repeat coronary revascularization (of the target vessel or non-target vessel) by either percutaneous or coronary artery bypass graft (CABG) methods, or stroke, at 30-days. In the case of patients presenting with non-ST elevation myocardial infarction, for the purposes of the primary and other endpoints, myocardial infarction will be defined as re-infarction following the PCI.", 
            "measure": "Major Adverse Cardiac Event (MACE) Rate", 
            "safety_issue": "Yes", 
            "time_frame": "30-days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02072421"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "All-cause mortality in hospital and at 30 days.", 
                "measure": "All-Cause Mortality", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "description": "Rate of stroke in hospital and at 30 days.", 
                "measure": "Stroke", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "description": "Rate of emergency or urgent revascularization in hospital and at 30 days.", 
                "measure": "Revascularization", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "description": "Procedure success defined as lesion success without the occurrence of in-hospital MACE.", 
                "measure": "Procedural Success", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "description": "Major vascular complications, including access site complications and major bleeding events requiring transfusion, in hospital and at 30 days.", 
                "measure": "Major Vascular Complications", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }
        ], 
        "source": "Harvard Clinical Research Institute", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Brockton Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Good Samaritan Hospital Medical Center, New York", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Norwood Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Holy Family Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Lawrence General Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Lowell General Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Melrose Wakefield Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Metro West Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Saints Memorial Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "South Shore Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Harvard Clinical Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2011", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}